Neuroendocrine tumours trials in United Kingdom
7 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Cambridge, Glasgow, London
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - Phase 3Taking peopleDAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
- Where
- Cambridge, Edinburgh, Manchester
- Age
- 18 years and over
- People
- 390 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00 - Phase 2/3Taking peopleZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Where
- Birmingham, Cardiff, Glasgow, Liverpool, London, Oxford, Sheffield, Sutton, Swansea
- Age
- 18 years and over
- People
- 440 worldwide
- Run by
- Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00 - Phase 1/2Not yet taking people in United KingdomDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Leicester, Newcastle upon Tyne
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00 - Phase 3Taking peopleStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Where
- Glasgow, London
- Age
- 12 years to 100 years
- People
- 240 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00 - Phase 2Taking peopleDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Leicester, London, Manchester, Newcastle upon Tyne
- Age
- 18 years and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00 - Phase 1Taking peopleLutathera and ASTX727 in Neuroendocrine Tumours
- Where
- London
- Age
- 18 years to 99 years
- People
- 27
- Run by
- Imperial College London
See details and how to joinNCT05178693